Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate

Satsuma Pharmaceuticals Inc STSA announced favorable safety, tolerability, and efficacy results from its recent analysis of the ongoing STS101 ASCEND Phase 3 trial.
The primary objective of the ASCEND trial is to assess the safety and tolerability of STS101 in the acute treatment of migraine attacks over 6 and 12 months.
No clinically relevant nasal safety or tolerability findings, clinically relevant systemic safety findings, or unexpected treatment-related serious adverse events were reported.
Among 172 trial participants who treated 1,932 migraine attacks exclusively with STS101, freedom from pain by 2 hours post-treatment was achieved in 34.2% of all treated attacks.
Freedom from most-bothersome-symptom by 2 hours post-treatment was achieved in 53.4% of all treated attacks.
In more than 81% of treated attacks, subjects did not report utilizing an allowed second dose of STS101 Mk2 within 48 hours of administering the first dose.
In more than 94% of treated attacks, subjects did not report utilizing rescue medications within 48 hours of administering STS101.
Price Action: STSA shares are up 14.1% at $7.93 on the last check Tuesday.